The Ontario Public Drug Programs Division (OPDP) recently announced amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act. The amendments include the establishment of a pricing framework for certain generic products approved for listing on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index on or after April 1, 2013, based on the number of competitor generic products available in the interchangeable group in the Canadian market. These amendments have been approved by the Ontario government and come into effect retroactively as of April 1, 2013.

With the implementation of this framework, the Ontario government hopes to increase transparency in pricing policy, and promote stability and predictability in the generic marketplace, while supporting its commitment to protect Ontario’s universal health care system.

For more information on the amendments, please see the authoritative text of the regulation on the government of Ontario website, as well as the Notice from the Executive Officer.